NEW YORK, Sept. 13, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation (“CytRx” or the “Company”) (NASDAQ:CYTR) between November 18, 2014 and July 11, 2016.
You are hereby notified that a securities class action has commenced in the USDC for the Central District of California. If you purchased or otherwise acquired CytRx securities between November 18, 2014 and July 11, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/cytrx-corporation.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts including: (1) that the clinical hold placed on the Phase 3 trial of aldoxorubicin for soft tissue sarcomas (“STSs”) would prevent sufficient follow-up for patients involved in the study; (2) that, as a result, nearly half of all patients would be excluded from the data since the study was disturbed by a partial clinical hold; (3) that, in response, CytRx would likely conduct a second analysis; (4) and that the results of the trial could be materially affected and/or approval of aldoxorubicin for STS could be delayed.
If you suffered a loss in CytRx you have until September 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/cytrx-corporation.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper
Shell M&A Chief Exits After BP Takeover Proposal Rejected
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 



